Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 9:8:212606.
doi: 10.7573/dic.212606. eCollection 2019.

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies

Manuel Anguita  1 , Mariano de la Figuera  2 , Alejandro I Pérez Cabeza  3 , Carmen Suarez Fernández  4
Affiliations

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies

Manuel Anguita et al. Drugs Context. .

Abstract

Aims: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain.

Methods: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies.

Results: Overall, mean age was 74.9±9.4 years, CHA2DS2-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high.

Conclusion: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high.

Keywords: ROCKET-AF; Spain; XANTUS; atrial fibrillation; clinical practice; rivaroxaban.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: MA has received funding for consultancy services and lecturing from Bayer, Daiichi-Sankyo and Pfizer. MDLF has received funding from Bayer Hispania for designing and publishing SILVER and BRONZE studies. APC has no conflict of interest to declare. CSF has received funding for consultancy services and lecturing from Bayer, Daiichi-Sankyo and Pfizer. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at http://www.drugsincontext.com/wp-content/uploads/2019/09/dic.212606-COI.pdf

References

    1. Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR., Jr Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective. J Am Coll Cardiol. 2018;71(24):2790–2801. doi: 10.1016/j.jacc.2018.04.013. - DOI - PubMed
    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Suárez Fernández C, Formiga F, Camafort M, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord. 2015;15:143. doi: 10.1186/s12872-015-0137-7. - DOI - PMC - PubMed
    1. Wehbe RM, Yadlapati A. Underuse of oral anticoagulants for nonvalvular atrial fibrillation: past, present, and future. Tex Heart Inst J. 2016;43(4):287–290. doi: 10.14503/THIJ-16-5785. - DOI - PMC - PubMed
    1. Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl Ed) 2012;65(1):47–53. doi: 10.1016/j.recesp.2011.08.008. - DOI - PubMed